A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
A phase 3 trial of Elranatamab, Daratumumab, Pomalidomide in multiple myeloma, run by Pfizer, now recruiting.
Overview
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments is a phase 3 interventional study registered as NCT05020236 by Pfizer, with 893 participants planned, started 2021-10-04 and due to reach its primary completion in 2026-02-26. Interventions recorded: Elranatamab, Daratumumab, Pomalidomide, Dexamethasone. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialAZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
Shares Elranatamab, Pomalidomide, Dexamethasone, Multiple myeloma.
- TrialA Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide
Shares Elranatamab, Daratumumab, Dexamethasone, Pfizer (incl. Seagen).
- TrialA Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma
Shares Pomalidomide, Daratumumab, Dexamethasone, Multiple myeloma.
- TrialMagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other
Shares Elranatamab, Pomalidomide, Dexamethasone, Pfizer (incl. Seagen).
- TrialA Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA)
Shares Pomalidomide, Daratumumab, Dexamethasone, Multiple myeloma.
- TrialA Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination Wi
Shares Pomalidomide, Daratumumab, Dexamethasone, Multiple myeloma.
- TrialA Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
Shares Pomalidomide, Daratumumab, Dexamethasone, Multiple myeloma.
- TrialStudy With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
Shares Elranatamab, Pfizer (incl. Seagen), Multiple myeloma.